Visceral Leishmaniasis

Categories: Bone diseases, Endocrine diseases, Gastrointestinal diseases, Immune diseases, Infectious diseases

Aliases & Classifications for Visceral Leishmaniasis

MalaCards integrated aliases for Visceral Leishmaniasis:

Name: Visceral Leishmaniasis 12 15 17 33
Leishmaniasis, Visceral 44 72
Infection by Visceral Leishmaniasis 12
Leishmaniasis Visceral 55
Kala-Azar 12


External Ids:

Disease Ontology 12 DOID:9146
ICD9CM 35 085.0
MeSH 44 D007898
NCIt 50 C34771
SNOMED-CT 68 48115004
ICD10 33 B55.0
UMLS 72 C0023290

Summaries for Visceral Leishmaniasis

Disease Ontology : 12 A leishmaniasis that is the most severe form of the disease caused by protozoan parasites of the Leishmania genus, resulting in the infection of the internal organs such as liver, spleen and bone marrow. The symptoms include fever, weight loss, and an enlarged spleen and liver.

MalaCards based summary : Visceral Leishmaniasis, also known as leishmaniasis, visceral, is related to leishmaniasis and hemophagocytic lymphohistiocytosis. An important gene associated with Visceral Leishmaniasis is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Lidocaine and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and bone, and related phenotypes are cellular and digestive/alimentary

Wikipedia : 75 Visceral leishmaniasis (VL), also known as kala-azar (UK: /EOkE'E?lET ETE^zE'E?r/), is the most severe... more...

Related Diseases for Visceral Leishmaniasis

Diseases related to Visceral Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 634)
# Related Disease Score Top Affiliating Genes
1 leishmaniasis 32.0 TNF TLR9 TLR4 TLR2 SLC11A1 NOS2
2 hemophagocytic lymphohistiocytosis 31.4 TNF IL10 IFNG CXCL8
3 immune deficiency disease 31.3 TLR9 IL4 IL2 IL10
4 mucocutaneous leishmaniasis 31.3 TNF TLR9 IL10
5 lymphopenia 31.2 IL2 IFNG FOXP3
6 acquired immunodeficiency syndrome 31.2 TNF IL2 IL10 IFNG ALB
7 conjunctivitis 31.0 IL4 IL2 IFNG CXCL8
8 hypersplenism 31.0 IFNG FOXP3 ALB
9 sleeping sickness 30.9 PGD NOS2 IL10
10 penicilliosis 30.9 TNF TLR4 TLR2
11 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.9 IL10 IFNG FOXP3
12 arthritis 30.9 TNF IL10 IFNG CXCL8
13 uveitis 30.9 TNF IL4 IL10 IFNG
14 neuritis 30.9 TNF IL4 IFNG
15 allergic hypersensitivity disease 30.8 TLR9 IL4 IL10 IFNG
16 leprosy 3 30.8 TNF TLR2 SLC11A1 IL2 IL10 IFNG
17 poliomyelitis 30.7 TNF IL4 IL10 IFNG
18 lichen planus 30.7 TNF TLR9 IL4 IFNG
19 plasmodium vivax malaria 30.7 TNF IL10 IFNG
20 schistosomiasis 30.7 TNF IL4 IL2 IL10 IFNG ALB
21 post-transplant lymphoproliferative disease 30.7 TNF SLC11A1 IL10
22 salmonellosis 30.7 TLR4 SLC11A1 IFNG ALB
23 mixed connective tissue disease 30.7 TNF IL10 IFNG
24 fascioliasis 30.7 IL10 IFNG ALB
25 hematopoietic stem cell transplantation 30.7 TNF IL2 IL10 IFNG
26 herpes zoster 30.6 IL2 IL10 IFNG
27 erythema multiforme 30.6 TNF IL2 IFNG
28 hepatitis a 30.6 TNF IL10 IFNG ALB
29 sarcoidosis 1 30.6 TNF SLC11A1 IL2 IFNG
30 exanthem 30.6 TNF TLR9 IL2
31 typhoid fever 30.6 TNF TLR4 SLC11A1 IFNG ALB
32 melioidosis 30.5 TNF TLR4 TLR2 IL10 IFNG
33 mumps 30.5 TNF IL2 IFNG
34 measles 30.5 TLR2 IL4 IL2 IFNG
35 keratitis, hereditary 30.5 TLR9 TLR4 TLR2
36 rheumatic disease 30.5 TNF TLR9 IL10 IFNG
37 tuberculous meningitis 30.4 TNF TLR2 CXCL8
38 tetanus 30.4 IL4 IL2 IL10 IFNG
39 echinococcosis 30.4 TNF TLR4 TLR2 IL10 IFNG
40 human immunodeficiency virus infectious disease 30.4 TNF TLR9 IL2 IL10 IFNG
41 connective tissue disease 30.4 TNF TLR9 IL10 IFNG
42 pulmonary edema 30.4 TNF IL10 CXCL8
43 graft-versus-host disease 30.4 TNF IL2 IL10 IFNG
44 osteomyelitis 30.3 TNF IL10 IFNG CXCL8
45 leptospirosis 30.3 TNF TLR2 IL10 IFNG CXCL8
46 crohn's disease 30.3 TNF TLR9 SLC11A1 IL10
47 cryptococcosis 30.3 TLR9 IL4 IFNG
48 hepatopulmonary syndrome 30.3 TNF NOS2 ALB
49 lepromatous leprosy 30.3 TNF TLR2 IL2 IL10 IFNG
50 pleurisy 30.3 TNF IL2 IFNG CXCL8

Graphical network of the top 20 diseases related to Visceral Leishmaniasis:

Diseases related to Visceral Leishmaniasis

Symptoms & Phenotypes for Visceral Leishmaniasis

MGI Mouse Phenotypes related to Visceral Leishmaniasis:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.33 ALB EEF2 FOXP3 IFNG IL10 IL2
2 digestive/alimentary MP:0005381 10.31 ALB FOXP3 IFNG IL10 IL2 IL4
3 hematopoietic system MP:0005397 10.27 FOXP3 IFNG IL10 IL2 IL4 NOS2
4 homeostasis/metabolism MP:0005376 10.26 ALB FOXP3 IFNG IL10 IL2 IL4
5 growth/size/body region MP:0005378 10.25 EEF2 FOXP3 IFNG IL10 IL2 IL4
6 immune system MP:0005387 10.23 FOXP3 IFNG IL10 IL2 IL4 NOS2
7 mortality/aging MP:0010768 10.21 ALB EEF2 FOXP3 IFNG IL10 IL2
8 endocrine/exocrine gland MP:0005379 10.18 ALB FOXP3 IFNG IL10 IL2 IL4
9 liver/biliary system MP:0005370 10.1 ALB FOXP3 IFNG IL10 IL2 IL4
10 integument MP:0010771 10.03 FOXP3 IFNG IL10 IL4 NOS2 TLR2
11 neoplasm MP:0002006 9.97 ALB IFNG IL10 IL2 NOS2 SLC11A1
12 normal MP:0002873 9.86 ALB FOXP3 IFNG IL10 IL4 TLR2
13 renal/urinary system MP:0005367 9.76 ALB FOXP3 IFNG IL4 NOS2 TLR2
14 respiratory system MP:0005388 9.61 FOXP3 IFNG IL10 IL2 IL4 NOS2
15 vision/eye MP:0005391 9.23 FOXP3 IFNG IL10 IL2 IL4 NOS2

Drugs & Therapeutics for Visceral Leishmaniasis

Drugs for Visceral Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
deoxycholic acid Approved Phase 4 83-44-3 222528
meglumine antimoniate Experimental, Investigational Phase 4 133-51-7
7 Anthelmintics Phase 4
8 Antimony Sodium Gluconate Phase 4
9 Anesthetics Phase 4
10 Antifungal Agents Phase 4
11 Liposomal amphotericin B Phase 4
12 Anti-Bacterial Agents Phase 4
13 Gastrointestinal Agents Phase 4
14 Amphotericin B, deoxycholate drug combination Phase 4
15 Cholagogues and Choleretics Phase 4
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
Pentamidine Approved, Investigational Phase 3 100-33-4 4735
Aluminum sulfate Approved Phase 2, Phase 3 10043-01-3
Paromomycin Approved, Investigational Phase 3 7542-37-2, 1263-89-4 165580
Nitric Oxide Approved Phase 3 10102-43-9 145068
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
22 Tocotrienol Investigational Phase 3 6829-55-6
23 Immunologic Factors Phase 2, Phase 3
24 Vaccines Phase 2, Phase 3
25 Vitamins Phase 3
26 Tocotrienols Phase 3
27 Tocopherols Phase 3
28 Adjuvants, Immunologic Phase 2, Phase 3
29 Antiparasitic Agents Phase 3
30 Antiprotozoal Agents Phase 3
31 Anti-Infective Agents Phase 3
32 Antioxidants Phase 3
33 Protective Agents Phase 3
34 Respiratory System Agents Phase 3
35 Free Radical Scavengers Phase 3
36 Neurotransmitter Agents Phase 3
37 Peripheral Nervous System Agents Phase 3
38 Endothelium-Dependent Relaxing Factors Phase 3
39 Vasodilator Agents Phase 3
40 Anti-Asthmatic Agents Phase 3
41 Autonomic Agents Phase 3
42 Bronchodilator Agents Phase 3
Miltefosine Approved, Investigational Phase 2 58066-85-6 3600
44 Parenteral Nutrition Solutions Phase 2
45 Fat Emulsions, Intravenous Phase 2
46 Pharmaceutical Solutions Phase 2
47 Soy Bean Phase 2
48 Soybean oil, phospholipid emulsion Phase 2
49 Thromboplastin Phase 1
Acetylcysteine Approved, Investigational 616-91-1 12035

Interventional clinical trials:

(show top 50) (show all 70)
# Name Status NCT ID Phase Drugs
1 Point of Care Diagnosis and Treatment With Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India. Unknown status NCT01566552 Phase 4 AMBISOME
2 Safety and Effectiveness of Short-course AmBisome in the Treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL): a Prospective Cohort Study in Bangladesh Completed NCT03311607 Phase 4 AmBisome
3 A Phase 4 Study to Expand Access Program While Assessing the Safety and Efficacy of Paromomycin IM Injection in an Outpatient Setting for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4 Paromomycin sulfate
4 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4 Mitefosine
5 Efficacy and Safety of Amphotericin B Deoxycholate Compared to Meglumine Antimoniate for Treatment of Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4 Meglumine antimoniate;Amphotericin B-deoxycholate
6 An Open Label Study of RFH Therapy as Treatment for CL Caused by Leishmania Tropica in India Completed NCT01661296 Phase 4 Sodium stibogluconate
7 Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study Recruiting NCT03814343 Phase 4 amphotericin B in 30% DMSO;30% DMSO
8 Multicentric Efficacy and Safety Study of Antileishmanial Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4 Antimoniate of N-methylglucamine;amphotericin B deoxycholate;Liposomal amphotericin B;Liposomal amphotericin B;Antimoniate of N-methylglucamine
9 A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of Amphomul® (Amphotericin B Emulsion) As Compared To Liposomal Amphotericin In Patients Of Visceral Leishmaniasis (Kala Azar) Completed NCT00876824 Phase 3 Amphotericin B Lipid emulsion;Liposomal Amphotericin B
10 A Multicentre Comparative Trial of Efficacy and Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) Versus Combination of SSG and PM as the First Line Treatment for Visceral Leishmaniasis in Ethiopia, Kenya and Sudan Completed NCT00255567 Phase 3 Sodium Stibogluconate;Paromomycin sulphate;SSG and Paromomycin sulphate
11 A Randomised, Open-label, Parallel-group, Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens (Co-administration), of AmBisome, Paromomycin and Miltefosine in Visceral Leishmaniasis (VL) Completed NCT00523965 Phase 3 amphotericin B deoxycholate;Liposomal Amphotericin B with Miltefosine;Liposomal Amphotericin B and Paromomycin Sulfate;miltefosine + Paromomycin sulfate
12 A Phase 3 Multicenter, Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Injectable Paromomycin in Patients With Visceral Leishmaniasis Completed NCT00216346 Phase 3 Paromomycin sulfate;Amphotericin B
13 A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL Completed NCT02193022 Phase 3 Miltefosine
14 Replacement of Insecticides to Control Visceral Leishmaniasis Completed NCT01644682 Phase 3
15 A Phase III Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Single Infusion of Liposomal Amphotericin B in Patients With Visceral Leishmaniasis Completed NCT00628719 Phase 3 Liposomal Amphotericin B;amphotericin B deoxycholate
16 An Open Lable Randomised Two -Arm Study to Assess the Safety and Efficacy of Paromomycin Administered Intramuscularly at Two Different Dosing Regimens (14 Days Versus 21 Days) for the Treatment of Indian Visceral Leishmaniasis (VL) Completed NCT00629031 Phase 3 Paromomycin;Paromomycin
17 Randomized, Open-label, Parallel-group, Safety & Efficacy Study to Evaluate Different Combination Treatment Regimens, of Either AmBisome and Paromomycin, AmBisome and Miltefosine, or Paromomycin and Miltefosine Compared With Amphotericin B Deoxycholate (the Standard) Therapy for the Treatment of Acute, Symptomatic Visceral Leishmaniasis (VL). Completed NCT00696969 Phase 3 Amphotericin B Deoxycholate;Ambisome + Miltefosine;Ambisome and Paromomycin;Miltefosine and Paromomycin
18 A Phase III, Open Label, Randomised, Study of Three Short Course Combination Regimens (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome® Alone for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh Completed NCT01122771 Phase 3 Liposomal amphotericin B;liposomal amphotericin B + miltefosine;liposomal amphotericin B + paromomycin;Miltefosine + Paromomycin
19 A Randomized Trial of Ambisome Monotherapy and Combination of Ambisome and Miltefosine for the Treatment of VL in HIV Positive Patients in Ethiopia Followed by Secondary VL Prophylactic Treatment With Pentamidine. Completed NCT02011958 Phase 3 Liposomal Amphotericin B;Miltefosine
20 Secondary Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients Using Pentamidine as a Prophylactic Agent: a Prospective Cohort Study Completed NCT01360762 Phase 3 Pentamidine
21 Phase 3, Clinical Trials of Drug Against Cutaneous Leishmaniasis Completed NCT00351520 Phase 3 Miltefose
22 A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania Major Plus BCG vs. BCG (Double Blind) or Placebo (Open), in Healthy High Risk Iranian Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
23 A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania Major Plus BCG vs. BCG (Double Blind) or Placebo (Open), in Healthy High Risk Iranian Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
24 An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Recruiting NCT03129646 Phase 3 Miltefosine;Paromomycin;Sodium stibogluconate
25 Double Blind, Randomized Controlled Trial, to Evaluate the Effectiveness of a Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Terminated NCT00317629 Phase 3 controlled nitric oxide releasing patch;meglumine antimoniate
26 A Prospective, Single Center, Open-Label, Dose-Escalation Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Treatment Naïve Or Resistant Cases Of Visceral Leishmaniasis (Kala-Azar). Completed NCT00497601 Phase 2 Amphotericin B fat emulsion in visceral leishmaniasis;Amphotericin B fat emulsion;Amphotericin B in fat emulsion
27 The Efficacy and Safety of a Short Course of Miltefosine and Liposomal Amphotericin B for Visceral Leishmaniasis in India Completed NCT00371995 Phase 2 Liposomal amphotericin B and Miltefosine
28 A Phase II, Multi-centre, Open-label, Randomised Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral Sitamaquine Compared With Amphotericin B in the Treatment of Visceral Leishmaniasis Caused by L. Donovani in Endemic Areas. Completed NCT00381394 Phase 2 sitamaquine
29 An Open-label Clinical Trial to Assess the Pharmacokinetics and Safety of Miltefosine Allometric Dose for the Treatment of Children With Primary Visceral Leishmaniasis in Eastern Africa Completed NCT02431143 Phase 2 Miltefosine
30 A Phase II Randomized, Parallel Arm, Open-labeled Clinical Trial to Assess the Safety and Efficacy of the Combination of Sodium Stibogluconate Plus Single Dose AmBisome®, Miltefosine Plus Single Dose AmBisome® and Miltefosine Alone for the Treatment of Primary Visceral Leishmaniasis in Eastern Africa Completed NCT01067443 Phase 2 Liposomal amphotericin B (AmBisome®) and sodium stibogluconate;Liposomal amphotericin B + miltefosine;Miltefosine
31 Combination Chemotherapy for the Treatment of Indian Visceral Leishmaniasis: Miltefosine Plus Liposomal Amphotericin B - Dose and Duration Ranging Study Completed NCT00370825 Phase 2 Combination therapy with AmBisome and miltefosine
32 Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL) Completed NCT01635777 Phase 2 Miltefosine;Miltefosine
33 Sodium Stibogluconate Treatment of Leishmaniasis Completed NCT00662012 Phase 2 Sodium Stibogluconate (SSG)
34 Department of Defense Protocol for the Use of Sodium Stibogluconate (Pentostam) as a Treatment for Leishmaniasis Completed NCT00657618 Phase 1, Phase 2 Sodium Stibogluconate (SSG)
35 An Open Label, Randomized, Parallel Arm Clinical Trial of Two Regimens to Assess the Safety and Efficacy for Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) Patients in Sudan Recruiting NCT03399955 Phase 2 Paromomycin;Ambisome;Miltefosine
36 A Phase IIa Safety Study to Assess the Safety and Immunogenicity of a New Leishmania Vaccine Candidate ChAd63-KH Active, not recruiting NCT02894008 Phase 2 ChAd63-KH
37 A Randomized, Open Label, Multicenter Study to Determine the Efficacy and Safety of Combining Thermotherapy and a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨ Active, not recruiting NCT02687971 Phase 2 Miltefosine
38 A Phase IIb Study to Assess the Safety, Efficacy and Immunogenicity of the Leishmania Vaccine ChAd63-KH in Post-kala Azar Dermal Leishmaniasis Not yet recruiting NCT03969134 Phase 2
39 Miltefosine for Brazilian Visceral Leishmaniasis Terminated NCT00378495 Phase 1, Phase 2 Miltefosine: initially 2.5 mg/kg/day for 28 days
40 Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With Visceral Leishmaniasis Terminated NCT00832208 Phase 2 Liposomal amphotericin B (Ambisome);Liposomal amphotericin B (Ambisome)
41 Phase II Proof of Concept Trial to Determine Efficacy of Fexinidazole in Visceral Leishmaniasis Patients in Sudan Terminated NCT01980199 Phase 2 Fexinidazole
42 A Phase I/II Clinical Trial To Assess the Safety and Biologic Activity of the Anti-IL-10 Monoclonal Antibody, SCH708980, in Combination With AmBisome(Registered Trademark), Versus That of Placebo in Combination With Ambisome(Registered Trademark), in Subjects With Visceral Leishmaniasis (VL) Withdrawn NCT01437020 Phase 1, Phase 2 SCH708980 Anti-IL-10 monoclonal;AmBisome
43 A Phase 1, Open-Label Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-F3 + SLA-SE Vaccine Compared to LEISH-F3 + GLA-SE Vaccine in Healthy Adult Subjects Completed NCT02071758 Phase 1
44 A Phase 1, Open-Label, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-111F + MPL-SE Vaccine (Recombinant Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE) in Healthy Adults In India Completed NCT00486382 Phase 1
45 Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine in Combination With SSG in the Treatment of Patients With PKDL Completed NCT00982774 Phase 1
46 A Phase 1, Randomized Clinical Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of The LEISH-F3 + GLA-SE Vaccine Compared To The LEISH-F3 Protein Alone In Healthy Adult Subjects Completed NCT01484548 Phase 1
47 A Phase I, Double-blind, Randomised, Single Centre, Parallel Group, Single-dose, Dose-escalation, Placebo Controlled Study of the Safety, Tolerability and Pharmacokinetics of DNDI-0690 After Oral Dosing in Healthy Male Subjects Recruiting NCT03929016 Phase 1 DNDI-0690;Placebo of DNDI-0690
48 Multi-Center, Open-Label, Randomized, Two Treatment, Parallel, Single Period, Multiple-Dose, Steady State, Global Bioequivalence Study of Amphotericin B Liposome for Injection 50mg /Vial in Patients With Visceral Leishmaniasis Recruiting NCT03636659 Phase 1 Amphotericin B Liposome;AmBisome (Amphotericin B) Liposome
49 Study for Evaluation of the Immune Response of Visceral Leishmaniasis Patients Treated With Antimonial Pentavalent Associated to N-Acetylcysteine Unknown status NCT01138956 N-acetylcysteine;Pentavalent antimonial
50 Visceral Leishmaniasis and Malnutrition in Amhara Regional State, Ethiopia Completed NCT02148822

Search NIH Clinical Center for Visceral Leishmaniasis

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Amphotericin B
Pentamidine Isethionate

Cochrane evidence based reviews: leishmaniasis, visceral

Genetic Tests for Visceral Leishmaniasis

Anatomical Context for Visceral Leishmaniasis

MalaCards organs/tissues related to Visceral Leishmaniasis:

Testes, T Cells, Bone, Bone Marrow, Liver, Spleen, Skin

Publications for Visceral Leishmaniasis

Articles related to Visceral Leishmaniasis:

(show top 50) (show all 7935)
# Title Authors PMID Year
Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis. 9 38
20404924 2010
Plasma lipoproteins in visceral leishmaniasis and their effect on Leishmania-infected macrophages. 9 38
20398226 2010
Immunologic indicators of clinical progression during canine Leishmania infantum infection. 9 38
20032217 2010
In situ immune responses to interstitial pneumonitis in human visceral leishmaniasis. 9 38
19149777 2009
Increased levels of IL-10, IL-12, and IFN- in patients with visceral leishmaniasis. 9 38
19578629 2009
Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis. 9 38
18948098 2009
IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. 9 38
17911647 2007
Interleukin-10 and the pathogenesis of human visceral leishmaniasis. 9 38
17689290 2007
Immunopathology of leishmaniasis: an update. 9 38
17880757 2007
Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. 9 38
17389235 2007
Cystatin C as a marker of immune complex-associated renal impairment in a Sudanese population with visceral leishmaniasis. 9 38
17123978 2006
Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection. 9 38
16968407 2006
Immunology of canine leishmaniasis. 9 38
16842269 2006
Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis. 9 38
16364177 2005
Leishmania donovani: effect of therapy on expression of CD2 antigen and secretion of macrophage migration inhibition factor by T-cells in patients with visceral leishmaniasis. 9 38
16023642 2005
Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs. 9 38
15619517 2005
Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. 9 38
15569785 2004
Adjunct effect of immunostimulating hexapeptide analogous to human beta-casein fragment (54-59) to sodium stibogluconate against experimental visceral leishmaniasis. 9 38
15518175 2004
Immunity and immunosuppression in experimental visceral leishmaniasis. 9 38
15064826 2004
Genetic control of visceral leishmaniasis in a Sudanese population: candidate gene testing indicates a linkage to the NRAMP1 region. 9 38
12618857 2003
Cellular profile of cytokine production in a patient with visceral leishmaniasis: gammadelta+ T cells express both type 1 cytokines and interleukin-10. 9 38
12641659 2003
Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. 9 38
12379707 2002
Tissue cytokine responses in canine visceral leishmaniasis. 9 38
11294678 2001
Reactive oxygen intermediates, nitrite and IFN-gamma in Indian visceral leishmaniasis. 9 38
11422203 2001
Association analysis of HLA-class II and class III gene polymorphisms in the susceptibility to mediterranean visceral leishmaniasis. 9 38
11334675 2001
Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines. 9 38
11280075 2001
IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. 9 38
10930301 2000
HIV-1 alters T helper cytokines, interleukin-12 and interleukin-18 responses to the protozoan parasite Leishmania donovani. 9 38
10853973 2000
Role of CD8+ T cells in endogenous interleukin-10 secretion associated with visceral leishmaniasis. 9 38
10733741 2000
High levels of C-reactive protein in the peripheral blood during visceral leishmaniasis predict subsequent development of post kala-azar dermal leishmaniasis. 9 38
10708005 2000
A novel Leishmania infantum recombinant antigen which elicits interleukin 10 production by peripheral blood mononuclear cells of patients with visceral leishmaniasis. 9 38
10639426 2000
Leishmania-specific T cells expressing interferon-gamma (IFN-gamma) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. 9 38
10361241 1999
T cell response of asymptomatic Leishmania chagasi infected subjects to recombinant leishmania antigens. 9 38
10348984 1999
Increased levels of soluble interleukin-4 receptor in the sera of patients with visceral leishmaniasis. 9 38
9952391 1999
T-cell response in human leishmaniasis. 9 38
10065635 1999
Splenic cytokine responses in Indian kala-azar before and after treatment. 9 38
9498473 1998
Human_leishmaniasis/ 9 38
9686193 1998
Cytokine profile and pathology in human leishmaniasis. 9 38
9686192 1998
High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. 9 38
9472662 1998
Presence of circulating levels of interferon-gamma, interleukin-10 and tumor necrosis factor-alpha in patients with visceral leishmaniasis. 9 38
9713135 1998
Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. 9 38
9333181 1997
Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines. 9 38
9164956 1997
Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. 9 38
9180602 1997
Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. 9 38
9120392 1997
Current and future clinical applications of interferon-gamma in host antimicrobial defense. 9 38
8923089 1996
Antimony/interferon-gamma combination in the treatment of visceral leishmaniasis in AIDS. 9 38
8874638 1996
Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis. 9 38
8648233 1996
Effect of treatment with interferon-gamma alone in visceral leishmaniasis. 9 38
7594733 1995
In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. 9 38
8580385 1995
Treatment of visceral leishmaniasis in a patient with AIDS with antimony and gamma-interferon: remission and prevention of relapse by maintenance therapy with weekly pentamidine. 9 38
7566284 1995

Variations for Visceral Leishmaniasis

Expression for Visceral Leishmaniasis

Search GEO for disease gene expression data for Visceral Leishmaniasis.

Pathways for Visceral Leishmaniasis

Pathways related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
13.44 TNF TLR9 TLR4 TLR2 IL4 IL2
Show member pathways
13.38 TNF NOS2 IL4 IL2 IL10 IFNG
Show member pathways
13.25 TNF TLR9 TLR4 TLR2 IL4 IL2
Show member pathways
Show member pathways
7 12.85 NOS2 IL4 IL2 IFNG CXCL8
Show member pathways
12.74 TNF TLR9 TLR4 TLR2 IL2
Show member pathways
12.66 TNF IL4 IL2 IL10 IFNG
Show member pathways
12.65 TNF TLR4 TLR2 IL4 IL2 IL10
Show member pathways
12.63 TNF NOS2 IL2 IL10 IFNG
Show member pathways
12.61 TNF IL4 IL2 IL10 IFNG
13 12.59 TNF TLR9 TLR2 IL4 IL2 IL10
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12.31 TNF TLR4 TLR2 NOS2 IL4 IL10
Show member pathways
22 12.25 TNF TLR9 TLR4 TLR2 NOS2 IL10
Show member pathways
12.24 TNF TLR9 IL2 IL10
Show member pathways
Show member pathways
12.11 IL4 IL2 IL10 IFNG CXCL8
26 12.09 TNF IL4 IL2 IL10 IFNG
Show member pathways
12.08 TLR9 TLR4 TLR2 IL2
28 12.07 TNF NOS2 IL4 IL10 CXCL8
Show member pathways
12.03 NOS2 IL4 IL2 IFNG
Show member pathways
11.98 TNF TLR9 TLR4 TLR2 IL2 IL10
32 11.95 TLR4 NOS2 IFNG
33 11.92 TNF TLR4 CXCL8
34 11.89 TNF IL4 IL2 IL10 IFNG
Show member pathways
11.88 TLR4 FOXP3 CXCL8
36 11.88 TLR4 IL2 CXCL8
37 11.88 TLR4 NOS2 IFNG CXCL8
38 11.88 TNF TLR4 NOS2 IL4 IL2 IFNG
39 11.87 IL4 IL2 IFNG CXCL8
40 11.86 TNF TLR4 NOS2 IL10 CXCL8
41 11.84 TNF TLR9 IL2 IL10 IFNG
42 11.83 TLR9 TLR4 TLR2
Show member pathways
Show member pathways
Show member pathways
Show member pathways
11.73 IL4 IL2 FOXP3
47 11.71 TNF TLR4 TLR2 NOS2 IL10 IFNG
48 11.7 TNF IL4 CXCL8
49 11.7 TNF NOS2 IL4 IL2 IL10 IFNG
50 11.69 TNF TLR4 TLR2 CXCL8

GO Terms for Visceral Leishmaniasis

Cellular components related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 TPI1 TNF IL4 IL2 IL10 IFNG
2 extracellular region GO:0005576 9.32 TNF TLR9 IL4 IL2 IL10 IFNG

Biological processes related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.97 TNF TLR9 TLR4 TLR2
2 defense response to Gram-negative bacterium GO:0050829 9.93 TLR9 TLR4 SLC11A1 NOS2
3 cellular response to interferon-gamma GO:0071346 9.91 TLR4 TLR2 NOS2
4 positive regulation of JNK cascade GO:0046330 9.9 TNF TLR9 TLR4
5 positive regulation of interleukin-6 production GO:0032755 9.9 TNF TLR9 TLR4 TLR2
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 IL4 IL2 IFNG
7 regulation of insulin secretion GO:0050796 9.89 TNF NOS2 IFNG
8 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.88 TNF TLR9 TLR4
9 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 TNF TLR9 TLR4 TLR2
10 cellular response to lipopolysaccharide GO:0071222 9.88 TNF TLR4 NOS2 IL10 HAMP CXCL8
11 positive regulation of tumor necrosis factor production GO:0032760 9.87 TLR9 TLR4 TLR2
12 negative regulation of tumor necrosis factor production GO:0032720 9.87 TLR4 IL10 FOXP3
13 defense response to bacterium GO:0042742 9.87 TNF TLR9 TLR4 SLC11A1 NOS2 IL10
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.86 TNF TLR4 IFNG
15 positive regulation of gene expression GO:0010628 9.86 TNF TLR9 TLR4 TLR2 SLC11A1 IL4
16 toll-like receptor signaling pathway GO:0002224 9.85 TLR9 TLR4 TLR2
17 positive regulation of inflammatory response GO:0050729 9.85 TNF TLR9 TLR4 TLR2 IL2
18 lipopolysaccharide-mediated signaling pathway GO:0031663 9.84 TNF TLR4 TLR2
19 positive regulation of interferon-gamma production GO:0032729 9.84 TNF TLR4 SLC11A1 IL2
20 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.83 TLR9 TLR4 TLR2
21 negative regulation of interferon-gamma production GO:0032689 9.83 TLR4 IL10 FOXP3
22 positive regulation of B cell proliferation GO:0030890 9.83 TLR9 TLR4 IL4 IL2
23 positive regulation of interferon-beta production GO:0032728 9.82 TLR9 TLR4 TLR2
24 positive regulation of interleukin-10 production GO:0032733 9.81 TLR9 TLR4 TLR2
25 regulation of regulatory T cell differentiation GO:0045589 9.8 IL2 IFNG FOXP3
26 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.79 TLR9 TLR4 TLR2
27 positive regulation of interleukin-8 production GO:0032757 9.78 TNF TLR9 TLR4 TLR2
28 negative regulation of interleukin-17 production GO:0032700 9.77 TLR4 IFNG FOXP3
29 I-kappaB phosphorylation GO:0007252 9.76 TLR9 TLR4 TLR2
30 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.74 TNF TLR9 TLR4
31 positive regulation of regulatory T cell differentiation GO:0045591 9.73 IL2 FOXP3
32 macrophage activation GO:0042116 9.73 TLR4 SLC11A1
33 positive regulation of interleukin-12 production GO:0032735 9.73 TLR9 TLR4 TLR2 IFNG
34 positive regulation of isotype switching to IgG isotypes GO:0048304 9.72 IL4 IL2
35 cellular response to lipoteichoic acid GO:0071223 9.72 TLR4 TLR2
36 multicellular organismal iron ion homeostasis GO:0060586 9.72 SLC11A1 HAMP
37 positive regulation of interferon-beta biosynthetic process GO:0045359 9.71 TLR9 TLR4
38 negative regulation of T-helper 17 cell differentiation GO:2000320 9.71 IL2 FOXP3
39 endothelial cell apoptotic process GO:0072577 9.71 TNF IL10
40 negative regulation of interleukin-8 production GO:0032717 9.71 TLR9 IL10
41 negative regulation of lymphocyte proliferation GO:0050672 9.7 IL2 FOXP3
42 negative regulation of cytokine secretion involved in immune response GO:0002740 9.7 TNF IL10
43 tumor necrosis factor production GO:0032640 9.7 TLR9 TLR2
44 positive regulation of interleukin-18 production GO:0032741 9.69 TLR9 TLR2
45 positive regulation of MHC class II biosynthetic process GO:0045348 9.69 TLR4 IL4 IL10
46 type 2 immune response GO:0042092 9.68 IL4 IL10
47 regulation of isotype switching GO:0045191 9.68 IL4 IL10
48 positive regulation of toll-like receptor signaling pathway GO:0034123 9.68 TLR9 TLR2
49 positive regulation of killing of cells of other organism GO:0051712 9.68 NOS2 IFNG
50 positive regulation of chemokine production GO:0032722 9.67 TNF TLR9 TLR4 TLR2

Molecular functions related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling pattern recognition receptor activity GO:0008329 9.16 TLR9 TLR2
2 cytokine activity GO:0005125 9.1 TNF IL4 IL2 IL10 IFNG CXCL8
3 lipopolysaccharide receptor activity GO:0001875 8.96 TLR4 TLR2

Sources for Visceral Leishmaniasis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....